Adaptive Phage Therapeuticsaptis A Clinical Stage Biotechnology Company Dedicated To Developing Phage Based Therapies For Antibiotic Resistant Bacterial Infectionsthe Company Specializes In Creating Personalized Bacteriophage Treatments Using A Proprietary Phage Librarytargeting Difficult To Treat Infections That Do Not Respond To Conventional Antibioticsapt Was Acquired By Biomx In March 2024Enhancing Its Capabilities With A Robust Pipeline That Includes Two Phase 2 Clinical Assets Apt S Core Technology Involves Isolating And Characterizing Bacteriophages To Develop Customized Treatments For Specific Bacterial Strainsthe Company Is Currently Conducting Phase 2 Trials For Musculoskeletal Infectionsincluding Prosthetic Joint Infections And Diabetic Foot Osteomyelitisapt Has Also Received Fda Clearance For Its Polymicrobial Phage Librarywhich Targets Complex Infections Caused By Multiple Pathogensthe Mission Of Apt Is To Improve Infection Treatment Through Precision Phage Therapyaiming To Reduce Reliance On Broad Spectrum Antibiotics And Address The Global Challenge Of Antimicrobial Resistance
